RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Research Lab (medical center)

Company


Owners:
R-Pharm

Content

Owners

History

2023: Establishment of the Centre

On October 19, 2023, it became known about the opening of the Research Lab drug research center in Moscow. This is a project of R-Pharm.

Research Lab on its website calls itself a research center for clinical research and offers to volunteer. The center is located in the building of the former Swiss Medica clinic on Annenskaya Street in Moscow.

It became known about the opening of the Research Lab drug research center

In January 2023, the center received a license, writes Kommersant. R-Pharm is now conducting bioequivalence studies of its generics only in this center, the newspaper learned from the register of clinical trials of the Ministry of Health. In three trials of other drugs of the company, other sites are used, noted the publication in the issue of October 19, 2023.

According to the Unified State Register of Legal Entities (USRUL), the founder of the Russian company R-Pharm Alexei Repik is the sole owner of Research Lab LLC, which manages the Research Lab medical center. Previously, 51% of the company belonged to Olga Filon, Director of the R-Farm Preclinical and Clinical Development Department. Eqiva consultant Maria Kolomentseva estimated the volume of investments in the creation of the center (including repairs and basic medical equipment) at 200-300 million rubles.

According to Natalya Rabinovich, general director of IFarm, the opening of a center for drug research is logical for R-Pharm, given the large number of generics in the manufacturer's portfolio. The new project will help the company itself organize and control tests without relying on third-party centers, believes Alexander Vasiliev, chief researcher of the Umedi network.

Kira Zaslavskaya, director of new products at Promomeda, noted in a commentary to the publication that she sees no point in focusing research efforts in one place, since, according to her, this does not provide wide access to patients with diseases and conditions for which the drugs are being tested.[1]

Notes